Cost-minimization analysis of phenytoin and fosphenytoin in the emergency department

Pharmacotherapy

Volumn 20, Issue 8I, 2000, Pages 908-916

  Touchette, Daniel R ^a   Rhoney, Denise H ^b,c  

^a OREGON STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c DETROIT RECEIVING HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOSPHENYTOIN SODIUM; PHENYTOIN;

ARTICLE; ATAXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; DRUG COST; DRUG INDUCED DISEASE; EMERGENCY WARD; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; PRURITUS; PURPLE GLOVE SYNDROME; RANDOMIZED CONTROLLED TRIAL; SEIZURE; VERTIGO;

ANTICONVULSANTS; COST CONTROL; EMERGENCY MEDICAL SERVICES; HUMANS; MODELS, ECONOMIC; MONTE CARLO METHOD; PHENYTOIN; PRODRUGS; PROSPECTIVE STUDIES; STATUS EPILEPTICUS;

EID: 0033843327     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.11.908.35269     Document Type: Article

References (30)

1. Epilepsy emergencies: The first seizure and status epilepticus
2. Phenytoin prodrugs. III. Water-soluble prodrugs for oral and/or parenteral use
3. Fosphenytoin: A novel phenytoin prodrug
4. Safety, tolerance and pharmacokinetics of intravenous fosphenytoin
5. Pharmacokinetics and tolerance of fosphenytoin and phenytoin administered intravenously to healthy subjects
6. Venous irritation related to intravenous administration of phenytoin versus fosphenytoin
7. Safety and pharmacokinetics of fosphenytoin following intravenous loading dose administration
8. Incidence of complications with intravenous administration of fosphenytoin
9. Intravenous phenytoin: Cheap but not necessarily a bargain
10. Complications of intravenous phenytoin for acute treatment of seizures. Recommendations for usage
11. Severe soft-tissue injury following intravenous infusion of phenytoin. Patient and drug administration risk factors
12. A prospective randomized evaluation of adverse events and length of stay associated with parenteral phenytoin or fosphenytoin use in the emergency department
13. A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx) versus intravenous phenytoin (Dilantin) in hospital emergency departments
14. A stepwise approach to performing a preliminary pharmacoeconomic analysis: Focus on phenytoin
15. Phenytoin and fosphenytoin: A model of cost and clinical outcomes
16. Decision analysis and pharmacoeconomic evaluations
17. Comparing health outcomes and costs: Subjective methods
18. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach
19. Cost determination and analysis
20. Extravasation of phenytoin in the hand
21. Extravasation of phenytoin and diazepam requiring surgical debridement and skin grafting
22. Extravasation injury to the hand by intravenous phenytoin. Report of three cases
23. Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin
24. Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin
25. Soft-tissue damage associated with intravenous phenytoin
26. Principles of pharmacoeconomic analysis of drug therapy
27. Assessing the impact of length of stay in a pharmacoeconomic analysis